CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is a specialty oncology biopharmaceutical company that completed its business combination with TenX Keane Acquisition Corp, a blank-check company sponsored by TenX Capital, bringing Citius Pharmaceuticals' oncology-focused assets into the public markets. TenX Keane conducted its initial public offering in 2021, targeting the healthcare and life sciences sector. The post-merger company, focused on developing and commercializing oncology and critical-care products, continues to trade under the TENK ticker on Nasdaq following the de-SPAC transaction. The August 2026 Form 8-K filing reflects ongoing public-company reporting obligations. For full transaction history, financials, and real-time SPAC data on Citius Oncology and hundreds of other deals, sign up for SpacDesk.